{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:44:05Z","timestamp":1740159845928,"version":"3.37.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T00:00:00Z","timestamp":1584144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T00:00:00Z","timestamp":1584144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s13318-020-00613-9","type":"journal-article","created":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T12:02:36Z","timestamp":1584187356000},"page":"467-475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["An Open-Label, Randomized, Single-Dose, Crossover, Comparative Pharmacokinetics Study of YLB113 and the Etanercept Reference Product in Healthy Adult Male Subjects"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3508-9522","authenticated-orcid":false,"given":"Mustafa","family":"Shennak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana","family":"Al-Jaouni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santhosh","family":"Kshirasagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi Sekhar","family":"Kasibhatta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neelima","family":"Godse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Al-Ghazawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praveen","family":"Vittala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhananjay","family":"Bakhle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,14]]},"reference":[{"issue":"2","key":"613_CR1","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2174\/1871530317666171114122417","volume":"18","author":"SA Fazal","year":"2018","unstructured":"Fazal SA, Khan M, Nishi SE, Alam F, Zarin N, Bari MT, et al. A clinical update and global economic burden of rheumatoid arthritis. Endocr Metab Immune Disord Drug Targets. 2018;18(2):98\u2013109. https:\/\/doi.org\/10.2174\/1871530317666171114122417.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"5 Suppl 1","key":"613_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.semarthrit.2005.01.004","volume":"34","author":"I Nestorov","year":"2005","unstructured":"Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum. 2005;34(5 Suppl 1):12\u20138. https:\/\/doi.org\/10.1016\/j.semarthrit.2005.01.004.","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"613_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1056\/NEJM199901283400401","volume":"340","author":"ME Weinblatt","year":"1999","unstructured":"Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340(4):253\u20139. https:\/\/doi.org\/10.1056\/NEJM199901283400401.","journal-title":"N Engl J Med"},{"issue":"12","key":"613_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s11926-018-0799-0","volume":"20","author":"L Chadwick","year":"2018","unstructured":"Chadwick L, Zhao S, Mysler E, Moots RJ. Review of biosimilar trials and data on etanercept in rheumatoid arthritis. Curr Rheumatol Rep. 2018;20(12):84. https:\/\/doi.org\/10.1007\/s11926-018-0799-0.","journal-title":"Curr Rheumatol Rep"},{"doi-asserted-by":"crossref","unstructured":"Combe C, Tredree RL, Schellekens H. Biosimilar epoetins: an analysis based on recently implemented European Medicines Evaluation Agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy. 2005;25(7):954\u201362.","key":"613_CR5","DOI":"10.1592\/phco.2005.25.7.954"},{"key":"613_CR6","volume-title":"Guideline on the investigation of bioequivalence","author":"European Medicines Agency","year":"2010","unstructured":"European Medicines Agency. Guideline on the investigation of bioequivalence. London: England; 2010."},{"issue":"2","key":"613_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2147\/btt.s1379","volume":"2","author":"B Combe","year":"2008","unstructured":"Combe B. Update on the use of etanercept across a spectrum of rheumatoid disorders. Biologics. 2008;2(2):165\u201373. https:\/\/doi.org\/10.2147\/btt.s1379.","journal-title":"Biologics."},{"unstructured":"Immunex Corporation. Enbrel (etanercept): prescribing information. Thousand Oaks, CA: Immunex Corporation; 2012.","key":"613_CR8"},{"issue":"4","key":"613_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40259-017-0230-9","volume":"31","author":"H Lee","year":"2017","unstructured":"Lee H, Chung H, Lee S, Lee H, Yang SM, Yoon SH, et al. LBEC0101, a proposed etanercept biosimilar: pharmacokinetics, immunogenicity, and tolerability profiles compared with a reference biologic product in healthy male subjects. BioDrugs. 2017;31(4):349\u201355. https:\/\/doi.org\/10.1007\/s40259-017-0230-9.","journal-title":"BioDrugs."},{"issue":"4","key":"613_CR10","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/bcp.13170","volume":"83","author":"O von Richter","year":"2017","unstructured":"von Richter O, Skerjanec A, Afonso M, Sanguino Heinrich S, Poetzl J, Woehling H, et al. GP2015, a proposed etanercept biosimilar: pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes. Br J Clin Pharmacol. 2017;83(4):732\u201341. https:\/\/doi.org\/10.1111\/bcp.13170.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"613_CR11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/bcp.12929","volume":"82","author":"YJ Lee","year":"2016","unstructured":"Lee YJ, Shin D, Kim Y, Kang J, Gauliard A, Fuhr R. A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel\u00ae) in healthy subjects. Br J Clin Pharmacol. 2016;82(1):64\u201373. https:\/\/doi.org\/10.1111\/bcp.12929.","journal-title":"Br J Clin Pharmacol"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-020-00613-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-020-00613-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-020-00613-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,14]],"date-time":"2021-03-14T00:26:52Z","timestamp":1615681612000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-020-00613-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,14]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["613"],"URL":"https:\/\/doi.org\/10.1007\/s13318-020-00613-9","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"type":"print","value":"0378-7966"},{"type":"electronic","value":"2107-0180"}],"subject":[],"published":{"date-parts":[[2020,3,14]]},"assertion":[{"value":"14 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Funding for the phase 1 study was provided by Lupin Ltd. Editorial assistance was provided under the direction of the authors by The Lynx Group LLC. Funding support for the manuscript was provided by Mylan Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mustafa Shennak is employed as Principal Investigator at Triumpharma. Rana Al-Jaouni is employed as Chief Operating Officer at Triumpharma. Santhosh Kshirasagar is employed as Assistant Director at Lupin Bioresearch Center in the Biopharmaceutics Department. Ravi Sekhar Kasibhatta is employed as Senior Vice President at Lupin Bioresearch Center. Neelima Godse is employed as a Research Scientist in the Medical Research Department of Lupin Limited (Research Park). Ahmad Al-Ghazawi is employed as President and Chief Executive Officer at Triumpharma. Praveen Vittala is employed as Assistant Director at Lupin Bioresearch Center in the Bioanalytic Research Department. Dhananjay Bakhle is employed as Executive Vice President\u2014Medical Research, Lupin Limited.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board of Triumpharma and were conducted in accordance with international clinical research guidelines and the principles enunciated in the 1964 Declaration of Helsinki and its later amendments, Good Clinical Practice, the Committee for Medicinal Products for Human Use guideline on the investigation of bioequivalence, and the local regulations and laws set by the Jordan Food and Drug Administration. The protocol of the study was approved by the IRB and the Ethical Committee of Triumpharma Research Institution of Amman, Jordan. The unique Jordan Food & Drug Administration trial number is 31\/Clinical\/2018.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}}]}}